FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
What happened
FDA reviewed a sponsored direct-to-consumer online video interview featuring Eli Lilly representatives, posted on okcfox.com and originally appearing July 11, 2025. FDA determined the video was false or misleading because it promoted Zepbound without communicating any risk information and omitted the drug's limitations of use. FDA also said the video was not submitted under Form FDA-2253 at initial publication.
What FDA found
The video promoted Zepbound without any risk information despite serious risks including a boxed warning for thyroid C-cell tumors.
21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5)The video omitted Zepbound's limitations of use, including that it is not recommended with other tirzepatide products or GLP-1 receptor agonists.
21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(3)(i)Eli Lilly did not submit the video to FDA under Form FDA-2253 at the time of initial publication.
21 CFR 314.81(b)(3)(i)
What FDA wants
FDA asks Eli Lilly to stop the misleading communications immediately and submit a written response within 15 working days, listing other similar Zepbound communications and a plan to discontinue them or cease distribution. FDA also requests a plan for corrective communications to the audience that received the video.
Who should pay attention
- drug advertising and promotional review teams
- pharmaceutical companies that use sponsored videos or social media
- telehealth and pharmacy platforms that host manufacturer-sponsored content
This is a summary. Read the original letter on fda.gov.